Insmed (INSM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ritu Baral from TD Cowen maintained a Buy rating on the stock and has a $98.00 price target.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ritu Baral’s rating is based on a combination of factors including Insmed’s robust financial performance and promising pipeline developments. Insmed reported strong global Arikayce revenue for the fourth quarter of 2024, surpassing previous estimates. This was complemented by a solid year-over-year growth projection for Arikayce in fiscal year 2025, indicating sustained demand and maturity in its market.
Moreover, the positive results from the Phase 3 ASPEN trial of brensocatib in NCFBE, showcasing significant efficacy and safety, further bolster the company’s prospects. With brensocatib granted priority review by the FDA and a PDUFA date set for August 2025, there is potential for a favorable regulatory outcome. These elements, combined with a substantial cash position, provide a strong foundation for future growth and support the Buy rating.
According to TipRanks, Baral is a 5-star analyst with an average return of 12.4% and a 47.39% success rate. Baral covers the Healthcare sector, focusing on stocks such as Insmed, Sarepta Therapeutics, and Alnylam Pharma.
In another report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $107.00 price target.